

**Accelerated Article Preview****Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia**

---

Received: 23 July 2020

---

Accepted: 25 March 2021

---

Accelerated Article Preview Published  
online 7 April 2021

---

Cite this article as: Braga, L. et al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia. *Nature* <https://doi.org/10.1038/s41586-021-03491-6> (2021).

---

Luca Braga, Hashim Ali, Ilaria Secco, Elena Chiavacci, Guilherme Neves, Daniel Goldhill, Rebecca Penn, Jose M. Jimenez-Guardeño, Ana M. Ortega-Prieto, Rossana Bussani, Antonio Cannatà, Giorgia Rizzari, Chiara Collesi, Edoardo Schneider, Daniele Arosio, Ajay M. Shah, Wendy S. Barclay, Michael H. Malim, Juan Burrone & Mauro Giacca

---

This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

# Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia

<https://doi.org/10.1038/s41586-021-03491-6>

Received: 23 July 2020

Accepted: 25 March 2021

Published online: 7 April 2021

Luca Braga<sup>1,9</sup>, Hashim Ali<sup>1,9</sup>, Ilaria Secco<sup>1</sup>, Elena Chiavacci<sup>1</sup>, Guilherme Neves<sup>2</sup>, Daniel Goldhill<sup>4</sup>, Rebecca Penn<sup>4</sup>, Jose M. Jimenez-Guardeño<sup>5</sup>, Ana M. Ortega-Prieto<sup>5</sup>, Rossana Bussani<sup>6</sup>, Antonio Cannata<sup>1</sup>, Giorgia Rizzari<sup>1</sup>, Chiara Collesi<sup>6,7</sup>, Edoardo Schneider<sup>1,7</sup>, Daniele Arosio<sup>8</sup>, Ajay M. Shah<sup>1</sup>, Wendy S. Barclay<sup>4</sup>, Michael H. Malim<sup>5</sup>, Juan Burrone<sup>2,3</sup> & Mauro Giacca<sup>1,6,7</sup>✉

COVID-19 is a disease with unique characteristics including lung thrombosis<sup>1</sup>, frequent diarrhoea<sup>2</sup>, abnormal activation of the inflammatory response<sup>3</sup> and rapid deterioration of lung function consistent with alveolar oedema<sup>4</sup>. The pathological substrate for these findings remains elusive. Here we show that the lungs of patients with COVID-19 contain infected pneumocytes with abnormal morphology and frequent multinucleation. Generation of these syncytia results from activation of the SARS-CoV-2 Spike protein at the cell plasma membrane level. Based on these observations, we performed two high-content microscopy-based screenings with over 3000 approved drugs to search for inhibitors of Spike-driven syncytia. We converged on the identification of 83 drugs that inhibited Spike-mediated cell fusion, several of which belonged to defined pharmacological classes. We focussed our attention on effective drugs that also protected against virus replication and associated cytopathicity. One of the most effective molecules was Niclosamide, which markedly blunted calcium oscillations and membrane conductances in Spike-expressing cells by suppressing the activity of TMEM16F/Anoctamin6, a calcium-activated ion channel and scramblase responsible for phosphatidylserine exposure on the cell surface. These findings suggest a potential mechanism for COVID-19 disease pathogenesis and support the repurposing of Niclosamide for therapy.

One of the defining features of coronavirus biology is the coordinated process by which the virus binds and enters the host cell, which involves both docking to receptors at the cell surface (ACE2 for SARS-CoV2<sup>5</sup>), and proteolytic activation of the Spike (S) protein by host encoded proteases at two distinct sites<sup>6</sup>. One activation step is Spike cleavage at the S1/S2 boundary, which can occur either before or after receptor binding. A second proteolytic activation exposes the S2 portion, and primes S2 for fusion of virus and cellular membranes. The protease priming event at this S2' site and subsequent fusion can occur after endocytosis, where cleavage is carried out by endosomal low pH-activated proteases such as cathepsin B and cathepsin L<sup>7</sup>, or at the plasma membrane, where cleavage can be mediated by TMPRSS2<sup>8–10</sup>. The Spike proteins of MERS-CoV and SARS-CoV-2 possess a multibasic amino acid sequence at the S1/S2 interface, which is not present in SARS-CoV<sup>11</sup>, that also allows cleavage by the ubiquitously expressed serine protease furin<sup>12–14</sup>. As a consequence, cells expressing MERS-CoV and SARS-CoV-2 Spike at the plasma membrane can fuse with other cells expressing the respective receptors and form syncytia.

## Pneumocyte syncytia in COVID-19 lungs

We examined the organs of 41 consecutive patients who died from COVID-19 in the period March–May 2020 at the University Hospital in Trieste, Italy. Detailed post-mortem analysis of these patients is reported elsewhere<sup>15</sup>. In addition to diffuse alveolar damage, frequent thrombosis and extensive fibrotic substitution, a peculiar finding was the presence, in almost 90% of these patients, of atypical cells with the characteristic of syncytia, showing a large cytoplasm containing a variable number of nuclei, ranging from 2 to over 20 (shown in Fig. 1a for 4 patients). Most of these syncytial cells were bona fide pneumocytes, as they expressed two pneumocyte-specific markers (napsin and surfactant B), and were positive for viral RNA by in situ hybridisation (Extended Data Figs. 1a and 1b).

## Fusogenic properties of Spike

The presence of fused cells in the lungs of COVID-19 patients likely results from the fusogenic activity of the SARS-CoV-2 Spike protein.

<sup>1</sup>King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK. <sup>2</sup>MRC Centre for Neurodevelopmental Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. <sup>3</sup>Centre for Developmental Neurobiology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. <sup>4</sup>Imperial College London, Department of Infectious Diseases, Imperial College London, London, United Kingdom. <sup>5</sup>Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom. <sup>6</sup>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy. <sup>7</sup>International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy. <sup>8</sup>Istituto di Biofisica (IBF), Consiglio Nazionale delle Ricerche (CNR), Trento, Italy. <sup>9</sup>These authors contributed equally: Luca Braga, Hashim Ali. ✉e-mail: mauro.giacca@kcl.ac.uk

In vitro, expression of a codon-optimised Spike protein cDNA in Vero cells led to the conspicuous presence of syncytia (Fig. 1b). Presence of Spike on the plasma membrane also triggered fusion of heterologous cells when these expressed the ACE2 receptor. Supplementary Video 1 shows the effect of co-culturing, for 12 hr, Spike-transfected human U2OS cells (which have undetectable levels of ACE2) with EGFP-transfected Vero cells. Progressive, heterologous cell fusion continued during the 12-hr observation period.

At higher magnification, Spike-expressing Vero cells and Spike-positive syncytia projected a remarkable number of plasma membrane protrusions, showing filopodia extensions and contacting the plasma membrane of neighbouring cells (Extended Data Fig. 1c). These Spike-expressing cells and syncytia displayed sudden calcium ( $\text{Ca}^{2+}$ ) transients in their cytoplasm, as visualised by transfecting the GCaMP6s fluorescent  $\text{Ca}^{2+}$  sensor (Supplementary Videos 2 and 3).

In contrast to SARS-CoV-2 Spike, no formation of syncytia was observed when Spike from SARS-CoV was expressed, while MERS-CoV Spike was also markedly syncytiogenic (Extended Data Figs. 1d and 1e).

### Screening for drugs that block syncytia

We wanted to find clinically approved drugs that inhibit SARS-CoV-2 Spike-mediated cell fusion. We developed two assays for high throughput screening (HTS) using high content imaging. The first was based on heterologous fusion between Vero and Spike-expressing U2OS cells (Cell Fusion Inhibition Assay, CFIA), while the second based on direct Spike expression in Vero cells (Syncytia Inhibition Assay, SIA). With these two assays, we screened two FDA/EMA-approved drug libraries (Prestwick Chemical Library and The Spectrum Collection, MS Discovery), totalling 3825 drugs. As 776 drugs are common in the two libraries, this amounts to 3049 different small molecules.

The CFIA and its results are detailed in Extended Data Figs. 2a–g. For SIA, we expressed Spike for 15 hr, incubated the cells with the drugs for an additional 24 hr and then imaged and quantified syncytia (Fig. 1c). This screening revealed 57 drugs from the Prestwick and 84 drugs from the MS Discovery library that inhibited Spike-mediated fusion with a z score  $< -1.96$  (0.025% tail of the distribution), of which 37 and 47 respectively had z scores  $< -2.58$  (0.005% tail; show in red in Fig. 1e and listed in Supplementary Information Table 2). All DMSO-treated (Control) wells for either library had a z score in the  $\pm 0.25$  range. The distribution of the results for each of the two libraries is shown in Extended Data Figs. 3a and b. As for CFIA, there was a significant correlation of effect for the common drugs in the two libraries (Extended Data Fig. 3c;  $P < 0.0001$ ;  $R^2 = 0.18$ ). Representative images from the screening are shown in Fig. 1f for Niclosamide, the top hit in the Prestwick and the second in the MS Discovery library, and in Extended Data Fig. 3d for other effective drugs. Dose-response curves for syncytia inhibition for three selected drugs (Niclosamide, Clofazimine and Salinomycin) are shown in Extended Data Figs. 3e for Vero and HEK293 cells. Extended Data Fig. 4a shows the results of the SIA screening according to therapeutic drug classes.

### Antiviral effect of drugs

The CFIA and SIA screenings cumulatively identified 83 drugs a z score  $< -2.58$  (Extended Data Fig. 4b). The choice for further studies took in consideration the following criteria: 1) common inhibitory effect in the two screenings; 2) relative efficacy within specific drug classes; 3) pharmacological suitability to clinical application. Based on these criteria, we assessed the effect of 43 drugs on SARS-CoV-2 infection (drug list in Extended Data Fig. 5a). Vero cells were infected with SARS-CoV-2 strain IC19/2020 (100 TCID<sub>50</sub> per well) in the presence of 10  $\mu\text{M}$  drugs in 96-well plates. The ability of drugs to protect cells from viral cytopathic effects was analysed after 5 days (Extended Data Fig. 5b). Of the most effective drugs, we selected one anti-histaminic (Deptropine), one antidepressant (Sertraline) and the antileprotic antibiotic

Clofazimine for further studies. Niclosamide and Salinomycin, which scored as cytotoxic at 10  $\mu\text{M}$  in the absence of the virus (not shown), were also shortlisted, as these drugs were among the most effective in the SIA screening.

The five selected drugs were further assessed for cell protection against virus-induced cell death in a range of doses, followed by the analysis of cell survival after 5 days. Niclosamide, Clofazimine and Salinomycin were most effective in this cell protection assay (Extended Data Fig. 5c) and were thus chosen for further testing of antiviral function.

Vero cells were infected in triplicate with SARS-CoV-2 (MOI 0.05) in the presence of escalating drug concentrations; culture supernatants were harvested 48 hr after viral challenge and infectious virus production was determined by plaque assay (Fig. 2a). Niclosamide and Salinomycin displayed similar IC<sub>50</sub> values of 0.34  $\mu\text{M}$  and 0.22  $\mu\text{M}$ , respectively, while Clofazimine was -10-fold less potent (IC<sub>50</sub> of 2.56  $\mu\text{M}$ ). All three drugs also inhibited viral replication in respiratory Calu-3 cells (Extended Data Fig. 5d). Representative images of Calu-3 syncytia infected with SARS-CoV-2 are shown in Extended Data Fig. 5e. Of note, the cells still infected in the presence of Niclosamide were no longer syncytial (Extended Data Fig. 5f).

### Anti-syncytial drugs block calcium release

We wanted to understand the mechanism(s) by which the selected drugs inhibited syncytia formation. We were intrigued by the observation that our assays had selected for specific drug classes. In particular, there were 11 antipsychotics, 8 antidepressants and 5 first-generation histamine 1 (H1) receptor antagonists among the top selected drugs. A common characteristic of these molecules is their capacity to regulate intracellular  $\text{Ca}^{2+}$  levels. The H1 receptor, M1, M2 and M5 muscarinic receptors, and the 5-HT<sub>2</sub> serotonin receptors signal through a G $\alpha$  subunit to activate PLC $\beta$ , which in turn hydrolyses PIP<sub>2</sub> to generate Ins(1,4,5)P<sub>3</sub> (IP<sub>3</sub>). IP<sub>3</sub> acts as a second messenger to activate  $\text{Ca}^{2+}$  release into the cytoplasm from the endoplasmic reticulum (ER) stores upon binding to IP<sub>3</sub>R<sup>16</sup>. Besides H1R antagonists and anticholinergics, phenothiazine antipsychotics and other tricyclics also act, to a different extent, on these receptors. Cyclosporin A forms a complex with cyclophilin, which, in platelets, inhibits Store-Operated- $\text{Ca}^{2+}$  Entry (SOCE) into cells through  $\text{Ca}^{2+}$ -release-activated  $\text{Ca}^{2+}$  (CRAC) channels<sup>17</sup>. Finally, the L-type  $\text{Ca}^{2+}$  channel blockers and most of the tricyclic antidepressants<sup>18</sup> inhibit the voltage-dependent L-type calcium channels, which are also expressed in epithelial cells, including HEK293 cells<sup>19</sup>.

Combining these considerations, we wanted to explore the dynamics of  $\text{Ca}^{2+}$  levels in cells expressing Spike and during cell fusion. We performed time-lapse imaging of Vero cells expressing the calcium indicator GCaMP6s<sup>20</sup>, co-cultured with U2OS cells expressing Spike and mCherry fluorescent protein. We observed that the Spike-expressing cells as well as the heterologous syncytia they formed had numerous oscillations in intracellular  $\text{Ca}^{2+}$  levels (Supplementary Video 4; individual frames in Fig. 2b). To obtain a quantitative measurement of these  $\text{Ca}^{2+}$  oscillations, we expressed GCaMP6s in Vero cells, with or without Spike, and imaged these cells for 400 min. Over this period, the cells expressing Spike progressively fused and had frequent  $\text{Ca}^{2+}$  oscillations (Supplementary Video 5, movie without drugs and individual frames in Fig. 2c). The oscillation traces for over 50 cells (or syncytia in the case of fused cells) are overlaid for each condition (Control or Spike) in Fig. 2d. The presence of Spike increased the amplitude of  $\text{Ca}^{2+}$  transients in individual cells ( $P < 0.01$ ; Extended Data Fig. 6a), without a significant difference in frequency, suggesting that Spike expression amplifies spontaneous  $\text{Ca}^{2+}$  transients. Expression of Spike from SARS-CoV was ineffective (Extended Data Figs. 7a and 7b), while Spike from MERS-CoV also induced  $\text{Ca}^{2+}$  oscillations. Both 1  $\mu\text{M}$  Niclosamide and 5  $\mu\text{M}$  Clofazimine markedly blunted both the amplitude and frequency of the  $\text{Ca}^{2+}$  oscillations in SARS-CoV-2 Spike-treated cells

(Fig. 2d and Extended Data Fig. 6b respectively;  $P < 0.01$ ). Salinomycin, while still inhibiting syncytia formation, was ineffective in these experiments. Representative movies showing these results are in Supplementary Video 5.

Cells treated for 400 min with thapsigargin (TG) or cyclopiazonic acid (CPA), two non-competitive inhibitors of the sarco/endoplasmic reticulum  $\text{Ca}^{2+}$  ATPase (SERCA), which cause ER  $\text{Ca}^{2+}$  store depletion<sup>21</sup>, abolished these oscillations, similar to removal of  $\text{Ca}^{2+}$  from the cell culture medium (Extended Data Figs. 6c and 6d). These results are consistent with the conclusion that the ER is the main source of  $\text{Ca}^{2+}$  release induced by the SARS-CoV-2 Spike. Of note, cell treatment with TG or CPA also inhibited expansion of syncytia while not impacting on cell viability (Figs. 3a and 3b and Supplementary Video 6).

### TMEM16F is required for syncytia

A hint to explain these findings was provided by the observation that Niclosamide is a potent inhibitor of the  $\text{Ca}^{2+}$ -activated TMEM16/Anoctamin family of chloride channels and scramblases<sup>22</sup>. We investigated the levels of the 10 members of this family in several cell lines and in primary bronchial human airway epithelial cells; Extended Data Fig. 8a). We found that TMEM16F, which functions both as a non-specific ion channel and a lipid scramblase responsible for phosphatidylserine (PS) externalisation onto the outer leaflet of the plasma membrane<sup>23</sup>, was expressed in all cells and that its levels further increased upon Spike expression (Extended Data Fig. 8b).

We wondered whether the activity of TMEM16F at the membrane was affected by Spike. We performed whole-cell voltage-clamp recordings of HEK293 cells to measure the endogenous currents carried by this channel. We recorded small but clearly detectable outwardly rectifying currents in response to voltage ramps. This current required high intracellular  $\text{Ca}^{2+}$  (28  $\mu\text{M}$ ), was blunted by the targeted knockdown of TMEM16F (Fig. 3d; RNA and protein levels to confirm knockdown are in Extended Data Fig. 9a for all the investigated cell types), was blocked by the TMEM16A and TMEM16F inhibitor benzbramarone (10  $\mu\text{M}$ ;  $P < 0.01$ ) and was reduced at lower intracellular  $\text{Ca}^{2+}$  (0.5  $\mu\text{M}$ ; Extended Data Fig. 10a). These results suggest that this current is carried, at least in part, by TMEM16F channels. We found that acute administration of Niclosamide (2  $\mu\text{M}$ ) readily blocked this current ( $P < 0.01$ ), while both Clofazimine (5  $\mu\text{M}$ ) and Salinomycin (5  $\mu\text{M}$ ) had no significant direct effect (Fig. 3c). Importantly, we found that HEK293 cells expressing Spike and ACE2 showed an increased current in response to voltage ramps (Fig. 3e;  $P < 0.05$ ), reflecting either an increase in TMEM16F expression (Extended Data Fig. 8b) or a direct modulation of channel activity. None of the investigated drugs changed the expression levels of either TMEM16A or TMEM16F (Extended Data Fig. 8c).

Collectively, these results indicate that SARS-CoV-2 Spike leads to the activation of TMEM16 proteins and that Niclosamide inhibits this activity. We thus wanted to explore the relationship between this effect and the suppression of syncytia. First, we found that the downregulation of TMEM16F inhibited  $\text{Ca}^{2+}$  transients induced by Spike (Extended Data Figs. 7c and 7d). In these experiments, an siRNA against ACE2 also had a similar suppressive effect, again underlining the relationship between  $\text{Ca}^{2+}$  oscillations, TMEM16F function and Spike-mediated cell-cell fusion. Then, we observed that the downregulation of TMEM16F almost completely suppressed PS externalization in Vero cells treated with the  $\text{Ca}^{2+}$  ionophore ionomycin (10  $\mu\text{M}$ ; Fig. 3f and Fig. 3g; complete set of images and magnification in Extended Data Figs. 10b and 10c), indicating that TMEM16F is the main cellular scramblase responsive to  $\text{Ca}^{2+}$  in these cells. In line with these observations, a 1 hr treatment with either Niclosamide or Clofazimine significantly reduced the levels of externalized PS in response to ionomycin (Figs. 3h and Fig. 3i; complete set of images in Extended Data Figs. 10d). Over 95% of cell nuclei remained negative to propidium iodide in these experiments, ruling out cell apoptosis (not shown). Consistent with TMEM16F activation,

several Spike-induced syncytia exposed PS on their plasma membrane (Extended Data Fig. 10e).

To confirm the specific involvement of TMEM16F in syncytia formation, we knocked down ACE2, TMEM16A and TMEM16F in Vero, HEK293 or Calu-3 cells. The downregulation of TMEM16F blunted syncytia formation in Spike-expressing cells, similar to an anti-ACE2 siRNA (Figs. 3j and 3k for Vero and HEK/ACE2 cells respectively). An analogous inhibitory effect of TMEM16F knockdown was observed in Calu-3 cells (Extended Data Figs. 11a and 11b; deconvolution of the TMEM16F siRNA commercial pool used in these experiments is in Extended Data Fig. 11c and 11d). Of interest for future investigation, TMEM16F knockdown had no apparent effect on syncytia induced by MERS-CoV Spike (Extended Data Figs. 11e and 11f). Conversely, overexpression of TMEM16F, but not of TMEM16A, significantly stimulated SARS-CoV-2 Spike-induced syncytia (Figs. 3l and 3m and high magnification in Extended Data Fig. 11g). Finally, we observed that Calu-3 cells in which TMEM16F was downregulated showed significantly impaired infectious SARS-CoV-2 replication (visualization of infected cells with anti-Spike and anti-N antibodies in Figs. 3n and 3p).

### Discussion

We envisage at least three mechanisms by which Spike can activate TMEM16 proteins. This can occur directly on the S-expressing (infected) cells in cis or upon binding to ACE2 and activating protease in trans, or indirectly through the activation of  $\text{Ca}^{2+}$  release. As far as the interplay between  $\text{Ca}^{2+}$  levels and TMEM16 proteins is concerned, TMEM16 activation by SARS-CoV-2 Spike appears to increase the amplitude of spontaneous  $\text{Ca}^{2+}$  signals. This is in line with previous reports showing that both TMEM16A and TMEM16F augment intracellular  $\text{Ca}^{2+}$  signals by increasing the filling of ER stores and augmenting IP3R-induced  $\text{Ca}^{2+}$  release, thus amplifying  $\text{Ca}^{2+}$  signals activated by GPCRs<sup>24,25</sup>.

The involvement of TMEM16F in SARS-CoV-2 Spike-induced syncytia is consistent with the previously proposed role of PS exposure in most other physiological cell fusion events. Macrophages fusing into inflammatory giant cells<sup>26</sup> or to form bone-reabsorbing osteoclasts<sup>27</sup>, myoblasts committed to fuse into myotubes<sup>28</sup>, cytotrophoblasts becoming syncytiotrophoblasts<sup>29</sup> and, finally, sperm cells during egg fertilisation<sup>30</sup> all expose PS at the cell surface. In the cases of myoblasts<sup>31</sup> and of placental development, TMEM16F<sup>32</sup> and TMEM16E<sup>31</sup>, respectively, were shown to specifically participate in this process.

From a mechanistic point of view, these findings are consistent with a model (Fig. 3q) by which the cells expressing SARS-CoV-2 Spike have increased  $\text{Ca}^{2+}$  oscillations and increased activity of the plasma membrane TMEM16 channels, which leads to PS externalization and chloride secretion. While the former event is required for plasma membrane fusion, chloride secretion might have relevance in COVID-19 pathogenesis.

Besides Niclosamide, other drugs known to inhibit the anoctamin/TMEM16 family also scored positive in inhibiting Spike-induced syncytia in our assays, including Nitazoxanide, Hexachlorophene and Dichlorophen. Gefitinib, which is known to block TMEM16A-activated EGFR on the plasma membrane<sup>33</sup>, also inhibited Spike-driven fusion. In addition, it appears likely that, similar to Niclosamide and Nitazoxanide<sup>22</sup>, other drugs that target TMEM16A (in particular, trifluoperazine<sup>34</sup>, serotonin reuptake inhibitors<sup>35,36</sup> and Ivermectin<sup>37</sup>, all of which scored positive against syncytia) might also inhibit TMEM16F. Thus, our screening for syncytia inhibition appears to have disclosed a common mechanism for Spike-dependent cell-cell fusion.

The activation of members of the TMEM16 family by SARS-CoV-2 Spike might have specific relevance for COVID-19 pathogenesis, as it could participate in inflammation (TMEM16A promotes NK- $\kappa$ B activation and IL-6 secretion<sup>38</sup>), thrombosis (TMEM16F is essential for lipid scrambling in platelets during blood coagulation<sup>39,40</sup>), dysfunction of endothelial cells<sup>41</sup> and alveolar oedema and diarrhoea through

increased chloride secretion. As a consequence, the identified drugs are worth considering for COVID-19 therapy. In particular, Niclosamide is a synthetic salicylanilide developed in the 1950s as a molluscicide against snails<sup>42</sup> and later approved in humans against tapeworm infection<sup>43</sup>. Niclosamide has already been reported to be active against various enveloped and non-enveloped viruses, including SARS-CoV-2<sup>44</sup>. Although this drug has relatively low solubility, there is evidence of considerable absorption, with serum levels that can reach 1–20  $\mu\text{M}$ <sup>45,46</sup>. Together, our findings provide a mechanism and a rationale for repurposing of Niclosamide to treat patients with COVID-19.


## Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-021-03491-6>.

- Levi, M., Thachil, J., Iba, T. & Levy, J. H. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol* **7**, e438–e440, [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9) (2020).
- Goyal, P. et al. Clinical Characteristics of Covid-19 in New York City. *N Engl J Med* **382**, 2372–2374, <https://doi.org/10.1056/NEJMc2010419> (2020).
- Jose, R. J. & Manuel, A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respir Med*, [https://doi.org/10.1016/S2213-2600\(20\)30216-2](https://doi.org/10.1016/S2213-2600(20)30216-2) (2020).
- Edler, C. et al. Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany. *Int J Legal Med* **134**, 1275–1284, <https://doi.org/10.1007/s00414-020-02317-w> (2020).
- Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271–280 e278, <https://doi.org/10.1016/j.cell.2020.02.052> (2020).
- Hoffmann, M., Hoffmann-Winkler, H. & Pohlmann, S. Priming Time: How Cellular Proteases Arm Coronavirus Spike Proteins. *Activation of Viruses by Host Proteases*, 71–98, [https://doi.org/10.1007/978-3-319-75474-1\\_4](https://doi.org/10.1007/978-3-319-75474-1_4) (2018).
- Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc Natl Acad Sci U S A* **102**, 11876–11881, <https://doi.org/10.1073/pnas.050557102> (2005).
- Glowacka, I. et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J Virol* **85**, 4122–4134, <https://doi.org/10.1128/JVI.02232-10> (2011).
- Matsuyama, S. et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. *J Virol* **84**, 12658–12664, <https://doi.org/10.1128/JVI.01542-10> (2010).
- Shulla, A. et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. *J Virol* **85**, 873–882, <https://doi.org/10.1128/JVI.02062-10> (2011).
- Millet, J. K. & Whittaker, G. R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. *Proc Natl Acad Sci U S A* **111**, 15214–15219, <https://doi.org/10.1073/pnas.1407087111> (2014).
- Burkard, C. et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. *PLoS Pathog* **10**, e1004502, <https://doi.org/10.1371/journal.ppat.1004502> (2014).
- Coutard, B. et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res* **176**, 104742, <https://doi.org/10.1016/j.antiviral.2020.104742> (2020).
- Hoffmann, M., Kleine-Weber, H. & Pohlmann, S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell* **78**, 779–784 e775, <https://doi.org/10.1016/j.molcel.2020.04.022> (2020).
- Bussani, R. et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. *Lancet EBioMedicine* **61**, 103104, <https://doi.org/10.1016/j.ebiom.2020.103104> (2020).
- Marks, A. R. Intracellular calcium-release channels: regulators of cell life and death. *Am J Physiol* **272**, H597–605, <https://doi.org/10.1152/ajpheart.1997.272.2.H597> (1997).
- Lang, F., Munzer, P., Gawaz, M. & Borst, O. Regulation of STIM1/Orai1-dependent Ca<sup>2+</sup> signalling in platelets. *Thromb Haemostasis* **110**, 925–930, <https://doi.org/10.1160/TH103-02-0176> (2013).
- Boselli, C., Barbone, M. S. & Lucchelli, A. Older versus newer antidepressants: substance P or calcium antagonism? *Can J Physiol Pharmacol* **85**, 1004–1011, <https://doi.org/10.1139/y07-089> (2007).
- Berjukow, S. et al. Endogenous calcium channels in human embryonic kidney (HEK293) cells. *Br J Pharmacol* **118**, 748–754, <https://doi.org/10.1111/j.1476-5381.1996.tb15463.x> (1996).
- Chen, T. W. et al. Ultrasensitive fluorescent proteins for imaging neuronal activity. *Nature* **499**, 295–300, <https://doi.org/10.1038/nature12354> (2013).
- Thastrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R. & Dawson, A. P. Thapsigargin, a tumor promoter, discharges intracellular Ca<sup>2+</sup> stores by specific inhibition of the endoplasmic reticulum Ca<sup>2+</sup>(+)-ATPase. *Proc Natl Acad Sci U S A* **87**, 2466–2470, <https://doi.org/10.1073/pnas.87.7.2466> (1990).
- Miner, K. et al. Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways. *Front Pharmacol* **10**, 51, <https://doi.org/10.3389/fphar.2019.00051> (2019).
- Suzuki, J., Umeda, M., Sims, P. J. & Nagata, S. Calcium-dependent phospholipid scrambling by TMEM16F. *Nature* **468**, 834–838 (2010).
- Jin, X. et al. Activation of the Cl<sup>-</sup> channel ANO1 by localized calcium signals in nociceptive sensory neurons requires coupling with the IP<sub>3</sub> receptor. *Sci Signal* **6**, ra73, <https://doi.org/10.1126/scisignal.2004184> (2013).
- Cabrera, I. et al. Differential effects of anoctamins on intracellular calcium signals. *FASEB J* **31**, 2123–2134, <https://doi.org/10.1096/fj.201600797RR> (2017).
- Helming, L. & Gordon, S. Molecular mediators of macrophage fusion. *Trends Cell Biol* **19**, 514–522, <https://doi.org/10.1016/j.tcb.2009.07.005> (2009).
- Verma, S. K. et al. Cell-surface phosphatidylserine regulates osteoclast precursor fusion. *J Biol Chem* **293**, 254–270, <https://doi.org/10.1074/jbc.M117.809681> (2018).
- van den Eijnde, S. M. et al. Transient expression of phosphatidylserine at cell-cell contact areas is required for myotube formation. *J Cell Sci* **114**, 3631–3642 (2001).
- Lyden, T. W., Ng, A. K. & Rote, N. S. Modulation of phosphatidylserine epitope expression by BeWo cells during forskolin treatment. *Placenta* **14**, 177–186, [https://doi.org/10.1016/s0143-4004\(05\)80259-0](https://doi.org/10.1016/s0143-4004(05)80259-0) (1993).
- Rival, C. M. et al. Phosphatidylserine on viable sperm and phagocytic machinery in oocytes regulate mammalian fertilization. *Nat Commun* **10**, 4456, <https://doi.org/10.1038/s41467-019-12406-z> (2019).
- Whitlock, J. M., Yu, K., Cui, Y. Y. & Hartzell, H. C. Anoctamin 5/TMEM16E facilitates muscle precursor cell fusion. *J Gen Physiol* **150**, 1498–1509, <https://doi.org/10.1085/jgp.201812097> (2018).
- Zhang, Y. et al. TMEM16F phospholipid scramblase mediates trophoblast fusion and placental development. *Sci Adv* **6**, eaba0310, <https://doi.org/10.1126/sciadv.aba0310> (2020).
- Bill, A. et al. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. *Oncotarget* **6**, 9173–9188, <https://doi.org/10.18632/oncotarget.3277> (2015).
- Tian, Y. et al. Calmodulin-dependent activation of the epithelial calcium-dependent chloride channel TMEM16A. *FASEB J* **25**, 1058–1068, <https://doi.org/10.1096/fj.10-166884> (2011).
- Maertens, C., Wei, L., Voets, T., Droogmans, G. & Nilius, B. Block by fluoxetine of volume-regulated anion channels. *Br J Pharmacol* **126**, 508–514, <https://doi.org/10.1038/sj.bjp.0702314> (1999).
- Yang, Y. D. et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. *Nature* **455**, 1210–1215, <https://doi.org/10.1038/nature07313> (2008).
- Zhang, X. et al. Inhibition of TMEM16A Ca<sup>2+</sup>-activated Cl<sup>-</sup> channels by avermectins is essential for their anticancer effects. *Pharmacol Res* **156**, 104763, <https://doi.org/10.1016/j.phrs.2020.104763> (2020).
- Wang, Q. et al. TMEM16A Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel inhibition ameliorates acute pancreatitis via the IP<sub>3</sub>/Ca<sup>2+</sup>/NFκB/IL-6 signaling pathway. *J Adv Res* **23**, 25–35, <https://doi.org/10.1016/j.jare.2020.01.006> (2020).
- Yang, H. et al. TMEM16F forms a Ca<sup>2+</sup>-activated cation channel required for lipid scrambling in platelets during blood coagulation. *Cell* **151**, 111–122, <https://doi.org/10.1016/j.cell.2012.07.036> (2012).
- Baig, A. A. et al. TMEM16F-Mediated Platelet Membrane Phospholipid Scrambling Is Critical for Hemostasis and Thrombosis but not Thromboinflammation in Mice-Brief Report. *Arterioscler Thromb Vasc Biol* **36**, 2152–2157, <https://doi.org/10.1161/ATVBAHA.116.307727> (2016).
- Ma, M. M. et al. TMEM16A Contributes to Endothelial Dysfunction by Facilitating Nox2 NADPH Oxidase-Derived Reactive Oxygen Species Generation in Hypertension. *Hypertension* **69**, 892–901, <https://doi.org/10.1161/HYPERTENSIONAHA.116.08874> (2017).
- Gonnert, R. & Schraufstatter, E. A new molluscicide: Molluscicide Bayer 73. *Proc. sixth Int. Congr. trop. Med. Malaria, Lisbon, Sept. 5-13, 1958* **2**, 197–202 (1959).
- Kappagoda, S., Singh, U. & Blackburn, B. G. Antiparasitic therapy. *Mayo Clin Proc* **86**, 561–583, <https://doi.org/10.4065/mcp.2011.0203> (2011).
- Jeon, S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. *Antimicrob Agents Chemother*, <https://doi.org/10.1128/AAC.00819-20> (2020).
- Andrews, P., Thyssen, J. & Lorke, D. The biology and toxicology of molluscicides, Bayluscide. *Pharmacol Ther* **19**, 245–295, [https://doi.org/10.1016/0163-7258\(82\)90064-x](https://doi.org/10.1016/0163-7258(82)90064-x) (1982).
- Burock, S. et al. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or synchronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. *BMC Cancer* **18**, 297, <https://doi.org/10.1186/s12885-018-4197-9> (2018).


**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2021




**Fig. 1 | Drugs inhibiting SARS-CoV-2 Spike-induced syncytia.** **a**, Post-mortem histological analysis of lungs of COVID-19 patients showing multinucleated syncytia, x40. Further information is in ref.<sup>15</sup>. **b**, Formation of syncytia after 24 hr Spike expression in Vero cells (nuclei in white, cell contours in red using wheat germ agglutinin (WGA), Spike in green). Scale bar: 200  $\mu$ m. **c**, Syncytia Inhibition Assay (SIA). **d**, Image analysis workflow; syncytia were defined as cells showing a cluster of nuclei with an area  $\geq 5$  times larger than the average of the area of non-fused cells. Scale bar: 500  $\mu$ m. **e**, Results of SIA screening. The percentage of syncytia normalized on total cells is plotted as z score.

Compounds with a z-score  $\leq -2.58$  (red dotted line, 0.005% tail) are shown in red, those between  $\leq -1.96$  (0.025% tail, blue dotted line) and  $-2.58$  in blue. Four drugs that were further studied with viral infection are indicated (NIC: Niclosamide; SAL: Salinomycin; CLO: clofazimine; SER: sertraline). **f**, Effect of Niclosamide on syncytia. Spike-positive syncytia are in green, nuclei in blue, cell body in red using HCS CellMask DeepRed. The percentage of nuclei within in syncytia over total nuclei is shown at the bottom. Scale bar: 500  $\mu$ m. Numbers on some of the images indicate the screening well. Representative image of 25/well, screening performed in duplicate.



**Fig. 2 | Effects of drugs on SARS-CoV-2 replication and intracellular calcium oscillations.** **a**, Inhibition of SARS-CoV-2 replication. Vero E6 cells were treated with the indicated drug concentrations for 2 hr, followed by the addition of SARS-CoV-2 (MOI 0.05). Data are mean  $\pm$  SD;  $n=3$ . After 1 hr, cells were washed and cultured in drug-containing medium for 48 hr. Virus production in the culture supernatants was quantified by plaque assay using Vero E6 cells. **b**, Representative frames (from a total of 600) from a 12-hr time lapse movie of a co-culture of Vero cells expressing the GCaMP6s Ca<sup>2+</sup> sensor and U2OS cells transfected with Spike and mCherry. Arrows indicate Ca<sup>2+</sup> oscillations in GCaMP6s-ACE2 expressing cells when fusing to Spike-expressing cells. The movie is in Supplementary Information Video 4. **c**, Ca<sup>2+</sup> oscillations during

syncytia formation. Representative frames (from a total of 400) from a 12-hr time lapse movie of Spike-expressing Vero cells. Arrows point at cells progressively fusing to a syncytium and showing intense Ca<sup>2+</sup> spikes. The movie is in Supplementary Information Video 5, upper left panel (DMSO control). **d**, GCaMP intensity over time. Vero cells were co-transfected with GCaMP6s and either a control or a Spike-expressing vector and treated with the indicated drugs. Data are expressed as  $\Delta F/F$  over time (min); every line is one of at least twelve 180  $\mu m^2$  ROI per condition, representing a group of 4 GCaMP-positive cells on average. Representative movies are in Supplementary Information Video 5.



**Fig. 3 | Calcium oscillations, chloride channel activity and requirement of TMEM16F protein for Spike-mediated cell-cell fusion.** **a** and **b**, Effect of  $Ca^{2+}$  depletion or treatment with thapsigargin (TG) or cyclopiazonic acid (CPA) on syncytia (cell area  $\geq 20,000 \mu m^2$ ). Scale bar:  $500 \mu m$ . Mean  $\pm$  SD;  $n=4$ .  $**P < 0.01$ , one-way ANOVA with Bonferroni post-hoc. **c-e**, Niclosamide-sensitive current is boosted by Spike/ACE2 and inhibited by TMEM16F knockdown. Currents were measured using a voltage ramp in HEK293 cells. In **c**, currents from control cells (black trace) were blocked by  $2 \mu M$  Niclosamide (NIC; blue). Inset shows current density at  $+75 mV$  for control cells ( $C, n=34$  cells) and cells treated with Niclosamide (NIC,  $n=7$ ), Salinomycin (SAL,  $n=8$ ) and Clofazimine (CLO,  $n=9$ ).  $**P < 0.01$ , Kruskal-Wallis, two-sided, with Dunn's post hoc. In **d**, cells transfected with control siRNA (siNT1; black,  $n=24$ ) or TMEM16F siRNA (blue,  $n=17$ ). Inset shows current density at  $+75 mV$ .  $**P < 0.01$ , Mann Whitney, two-sided. In **e**, cells transfected with EGFP (black,  $n=34$ ; same as in **c**) or EGFP/Spike/ACE2 (red,  $n=29$ ). Inset shows current density at  $+75 mV$ .  $*P < 0.05$ , Mann Whitney, two-sided. All value: mean  $\pm$  SEM. **f** and **g**, Annexin XII after TMEM16F knockdown ( $n=3$ ). Scale bar:  $500 \mu m$ . Statistics as in **b**. **h** and **i**, Annexin XII after

treatment with Niclosamide  $100 nM$ , Clofazimine or Salinomycin  $500 nM$  ( $n=3$ ). Scale bar:  $500 \mu m$ . Statistics as in **b**, **j** and **k**, Inhibition of syncytia by siRNAs. Cells treated with the indicated siRNAs and, after 24 hr, transfected to express Spike ( $n=3$ ). Scale bar:  $200 \mu m$ . Mean  $\pm$  SD.  $*P < 0.05$ ,  $**P < 0.01$ , one-way ANOVA with Dunnett post-hoc. **l** and **m**, Overexpression of TMEM16F induces syncytia. HEK293/ACE2 cells were co-transfected with Spike and TMEM16A or TMEM16F ( $n=3$ ). Statistics as in **b**. **n** and **p**, Inhibition of SARS-CoV-2 infection by siRNAs. Calu-3 cells were silenced for the indicated genes and, after 48 hr, infected with SARS-CoV-2 (MOI 0.5). One hr after infection, cells were washed and incubated with fresh medium. After 48 hr, cells were immunostained for Spike and Nucleocapsid. Scale bar:  $500 \mu m$ . Mean  $\pm$  SEM;  $n=4$ .  $**P < 0.01$ , one-way ANOVA with Dunnett post-hoc. **q**, Model showing the effect of drugs on syncytia and TMEM16F. Spike-expressing cells have increase  $Ca^{2+}$  (in orange) oscillations, leading to increased TMEM16F activity, which itself boosts  $Ca^{2+}$  levels. As a consequence, chloride (blue) secretion is increased, and PS (pink) is externalised. Drugs blocking TMEM16F or blunting  $Ca^{2+}$  release inhibit Spike-induced syncytia.

# Article

## Methods

No statistical methods were used to predetermine sample size. The investigators were not blinded to allocation during experiments and outcome assessment, except where specified below.

### Patients

Patients' lung samples are from post-mortem analysis of 6 patients who died of COVID-19 at the University Hospital in Trieste, Italy after intensive care support. These are from a more extensive cohort of 41 consecutive patients, all deceased of the disease. Of these, 25 males and 16 females; the average age was 77 for males and 84 for females. During hospitalization, all patients scored positive for SARS-CoV-2 on nasopharyngeal swab and presented symptoms and imaging data indicative of interstitial pneumonia related to COVID-19 disease. Extensive characterization of these patients is reported in ref. <sup>15</sup>. In these patients, dysmorphic and syncytial pneumocytes were present and abundant in the lungs of 20 patients (50%), including all 6 patients requiring intensive care, and occasional in additional 16 patients (39%). Use of these post-mortem samples for investigation was approved by the competent Joint Ethical Committee of the Regione Friuli Venezia Giulia, Italy (re. 0019072/P/GEN/ARCS).

### Cells

Vero(WHO) Clone 118 cells (ECACC 88020401) were cultured in Dulbecco's modified Eagle medium (DMEM, Life Technologies) with 1 g/L glucose (Life Technologies) supplemented with 10% heat-inactivated foetal bovine serum (FBS, Life Technologies) plus a final concentration of 100 IU/ml penicillin and 100 (µg/ml) streptomycin or without antibiotics where required for transfection. Cells were incubated at 37 °C, 5% CO<sub>2</sub>.

Vero E6 cells were kindly provided by Andrew Davidson and David Matthews, University of Bristol UK. Cells were grown in DMEM (Gibco) containing 10% FBS, 1% Non-essential Amino Acids (Gibco) and 1% penicillin-streptomycin (Thermo Fisher Scientific). Cells were incubated at 37 °C, 5% CO<sub>2</sub>.

U-2 OS (U2OS; ATCC HTB-96), HEK293T (ATCC CRL-3216) and Calu-3 cells (ATCC HTB-55) were cultured in Dulbecco's modified Eagle medium (DMEM) with 1 g/L glucose (Life Technologies) supplemented with 10% foetal bovine serum (FBS) (Life Technologies) plus a final concentration of 100 IU/ml penicillin and 100 (µg/ml) streptomycin or without antibiotics where required for transfections.

The stable U2OS cell clone expressing mCherry was obtained by transduction with lentiviral particles for constitutive expression of mCherry (rLV.EF1.mCherry-9, Takara 0037VCT) at 10 M.O.I with 4 µg/ml polybrene (Sigma-Aldrich TR-1003-G). The medium was replaced after 4 hr. Selection of the transduced cells was performed adding 1 µg/ml puromycin (InvivoGen ant-pr-1) starting 48 hr after transduction. Expression of the transgene was verified by fluorescence microscopy.

Primary bronchial human airway epithelial cells were purchased from Epithelix and maintained in Mucilair cell culture medium (Epithelix).

### Antibodies

Antibodies against the following proteins were used: TMEM16A (Abcam, ab64085), TMEM16F (Abcam ab234422 and Sigma-Aldrich HPA038958-100UL), ACE2 (Abcam ab87436 and ab15348), V5 (Thermo Fisher Scientific R96025), V5-488 (Thermo Fisher Scientific 377500A488), mouse-HRP (Abcam ab6789), rabbit-HRP (Abcam ab205718), β-actin-HRP (Sigma-Aldrich A5316), Napsin (Roche 760-4867), Surfactant B (Thermo Fisher Scientific MS-704-PO), mouse-Biotin (Vector Laboratories BA-9200), SARS-CoV-2 Spike protein (GeneTex GTX632604), SARS-CoV-2 Nucleocapsid antibody (Sino Biological 40143-R001).

### Cell Fusion Inhibition Assay (CFIA)

"Donor" U2OS cells were seeded in 10-cm Petri dishes (2 million cells per dish) to reach 70-80% confluency on the subsequent day. Transfection was performed using 10 µg of either pEC117-Spike-V5 (expressing the V5-tagged Spike protein, codon optimised) or a control vector using 35 µl of FuGENE HD Transfection Reagent (Promega E2311) in 500 µl of Opti-MEM medium (Life Technologies). After overnight transfection, cells were loaded with 10 nM Qtracker 525 Cell Labeling Kit (Invitrogen Q25041MP) in 1 ml of medium for 1 hr at 37 °C in 5% CO<sub>2</sub>. After extensive washes with 1xPBS, cells were detached with 1x Versene (Thermo Fisher Scientific 15040066). "Acceptor" Vero cells were prepared as follows. Cells were seeded in 10 cm Petri dishes (1.2 million cells per dish) the day before the assay. Cells were then loaded with 10 nM Qtracker 800 Cell Labelling Kit (Invitrogen Q25071MP) in 1 ml medium for 1 hr at 37 °C in 5% CO<sub>2</sub>. After extensive washes with 1xPBS, cells were detached with 0.05% Trypsin-EDTA (Sigma-Aldrich T4049). Vero and U2OS cells were mixed at the final ratio of 5:4 and diluted at the final concentration of 20x10<sup>3</sup> cells/ml in Dulbecco's modified Eagle medium (DMEM) with 1 g/L glucose (Life Technologies) supplemented with 10% heat-inactivated foetal bovine serum (FBS; Life Technologies). Diluted cells (50 µl/well, 1000 cells/well) were seeded in twelve 384-well microplates (CellCarrierUltra 384, Perkin Elmer) using a Multidrop dispenser. Three hours after seeding, drugs from The Spectrum Collection, MicroSource (MS) Discovery System Inc. (2545 different drugs) and the Prestwick Chemical Library, Prestwick Chemical (1280 drugs) were dispensed on top of cells at the final concentration of 10 µM (1% DMSO final). Twenty-four hours later plates were washed in 50 µl/well PBS and fixed in 40 µl 4% PFA for 10 min at room temperature (RT). After fixation, cells were washed two times in 50 µl/well PBS and permeabilized in 0.1% Triton X100 (Sigma-Aldrich 1086431000) for 10 min at RT. Cells were washed two times in 50 µl/well of PBS and stained with HCS CellMask Blue (Thermo Fisher Scientific H32720) and Hoechst (H3570), according to the manufacturer's instructions.

Image acquisition was performed using an Operetta CLS high content screening microscope (Perkin Elmer) with a Zeiss 20x (NA=0.80) objective. A total of 25 fields per well were imaged at 3 different wavelengths: 1) Excitation (Ex) 365-385nm, Emission (Em) 430-500nm (nucleus and cytoplasm "Blue"); 2) Ex 460-490nm, Em 500-550 nm (Donor quantum dots "Green"); 3) Ex 615-645nm Em 655-750nm (Acceptor quantum dots "Red"). Images were subsequently analysed, using the Harmony software package (v. 4.9; PerkinElmer). Images were first flatfield-corrected and nuclei were segmented using the "Find Nuclei" analysis module (Harmony). The thresholds for image segmentation were adjusted according to the signal-to-background ratio. Splitting coefficient was set in order to avoid splitting of overlapping nuclei (fused cells). The cytoplasm area, stained by the HCS Cell Mask Blue, was defined using the "Find Cytoplasm" analysis module (Harmony) and the number of either green or red spots was counted using the "Find Spots" analysis module (Harmony). All the cells that had a nuclear area greater than 4 times the average area of a single nucleus and were simultaneously positive for at least two red and two green dots were considered as fused. Data were expressed as a percentage of fused cells by calculating the average number of fused cells normalized on the total number of cells per well.

### Syncytium Inhibition Assay (SIA)

Vero cells were seeded in 10-cm Petri dishes (1.2 million cells per dish) to reach 70-80% confluency on the subsequent day. Transfection was performed using 10 µg pEC117-Spike-V5 using 30 µl and FuGENE HD Transfection Reagent (Promega E2311) in 500 µl of Opti-MEM medium (Life Technologies). Twelve hours after transfection, cells were detached, washed in 1xPBS and diluted to the final concentration of 12x10<sup>3</sup> cells/ml in Dulbecco's modified Eagle medium (DMEM) with 1 g/L glucose (Life Technologies) supplemented with 10% heat-inactivated FBS

(Life Technologies). Fifty  $\mu\text{l}$  diluted cell suspension (600 cells/well) were seeded in twelve 384-well microplates (CellCarrierUltra 384, Perkin Elmer) using a Multidrop dispenser. Three hours after seeding, drugs from The Spectrum Collection, MicroSource (MS) Discovery System Inc. (2545 different drugs) and the Prestwick Chemical Library, Prestwick Chemical (1280 drugs) were dispensed on top of the cells at the final concentration of 10  $\mu\text{M}$  (1% DMSO final). At 24 hr after drug treatment, plates were washed in 50  $\mu\text{l}$ /well of 1xPBS and fixed in 40  $\mu\text{l}$  4% PFA for 10 min at RT. After fixation, cells were processed for immunofluorescence using anti V5, Hoechst (H3570) and HCS CellMask Red (Thermo Fisher Scientific H32712), according to the manufacturer's instructions.

Image acquisition was performed using the Operetta CLS high content screening microscope (Perkin Elmer) with a Zeiss 20x (NA=0.80) objective. A total of 25 fields per well were imaged at 3 different wavelengths: 1) Excitation (Ex) 365-385nm, Emission (Em) 430-500nm (nucleus "Blue"); 2) Ex 460-490nm, Em 500-550nm (Spike protein "Green"); 3) Ex 615-645nm Em 655-750nm (HCS Cell Mask "Red"). Images were subsequently analysed, using the Harmony software (PerkinElmer). Images were first flatfield-corrected and nuclei were segmented using the "Find Nuclei" analysis module (Harmony). The thresholds for image segmentation were adjusted according to the signal-to-background ratio. Splitting coefficient was set in order to avoid splitting of overlapping nuclei (fused cells). The cytoplasm area, stained by the HCS Cell Mask Red, was defined using the "Find Cytoplasm" analysis module (Harmony) and the intensity of the green fluorescence was calculated using the "Calculate Intensity Properties" module (Harmony). All the cells that had a nuclear area greater than 5 times the average area of a single nucleus and were simultaneously positive for green signal in the cytoplasm area were considered as fused. Data were expressed as a percentage of fused cells by calculating the average number of fused cells normalized on the total number of cells per well.

### Immunofluorescence

After fixation in 4% PFA for 10 min at RT, cells were washed two times in 50  $\mu\text{l}$ /well (384 well-plate) or 100  $\mu\text{l}$ /well (96-well plate) of 1xPBS and then permeabilized in same volumes of 0.1% Triton X100 (Sigma-Aldrich 1086431000) for 10 min at RT. Cells were then washed two times 1xPBS and blocked in 1% BSA for 1 hr at RT. After blocking, the supernatant was removed, and cells were stained according to type of staining, as follows

V5 epitope staining. After blocking, the supernatant was removed and 20  $\mu\text{l}$ /well (384 well-plate) or 40  $\mu\text{l}$ /well (96-well plate) of diluted (1:1000 in 1%BSA) V5 Tag Alexa Fluor 488 Monoclonal Antibody (Thermo Fisher Scientific 37-7500-A488) was added to each well and incubated at RT for 2 hr. Cells were then washed two times in 1xPBS. Nuclear staining was performed by Hoechst 33342 according to the manufacturer's instruction.

SARS-CoV-2 Spike and Nucleocapsid, and cellular TMEM16F staining. After blocking, the supernatant was removed and 40  $\mu\text{l}$ /well (96-well plate) diluted primary antibody (1:500 in 1%BSA SARS-CoV-2 Spike antibody [1A9], GeneTex GTX632604; TMEM16F antibody, Sigma-Aldrich HPA038958, 1:3000 in BSA; and SARS-CoV-2 Nucleocapsid antibody, Sino Biological 40143-R001) was added to each well and incubated overnight at 4 °C. Cells were then washed two times in 1xPBS, the supernatant was removed and same volumes of diluted (1:500 in 1%BSA) secondary antibody were added to each well and incubated 2 hr. Cells were then washed two times in 1xPBS. Nuclear staining was performed by Hoechst 33342 according to the manufacturer's instructions.

Cytoplasmic staining. Cytoplasmic staining was performed by HCS Cell Mask Deep Red Staining (Invitrogen H32721) or HCS Cell Mask Blue Staining (H32720) according to the manufacturer's instructions.

### Histology and immunohistochemistry

Samples from COVID-19 autopsies were fixed in 10% formalin for at least 50 hours and then embedded in paraffin. Four-micron sections were deparaffinized in xylene, rehydrated and processed for hematoxylin-eosin or immunohistochemical stainings. Antigen retrieval was performed in boiling sodium citrate solution (0.01 M, pH 6.0) for 20 min. Sections were allowed to cool down and permeabilized for 10 min in 1% Triton X-100 in 1xPBS, followed by blocking in 2% BSA (Roche) and overnight staining at 4 °C with the primary antibodies diluted in blocking solution. After endogenous peroxidase inhibition with 3%  $\text{H}_2\text{O}_2$ , sections were incubated with appropriate biotin-conjugate secondary antibody for 1 hr at room temperature. Following signal amplification with avidin-biotin-complex-HRP (Vectastain), DAB solution (Vector) was applied for 2-3 min. Haematoxylin (Bioptica) was further used to stain nuclei and Bluing reagent was used on Ventana automated stainings. Images were acquired using a Leica ICC50W light microscope.

### In situ hybridization

In situ hybridization (ISH) was performed using locked nucleic acid (LNA) probes for U6 snRNA<sup>47</sup> and SARS-CoV-2 RNA, designed to target the sense strand of ORF1ab and Spike regions of the viral genome. Scrambled sequences were used as control. Experiments were performed using a dedicated ISH kit for Formalin-fixed paraffin-embedded (FFPE) tissues (Qiagen) according to the manufacturer's protocol. Briefly, FFPE tissue slides were deparaffinized in xylene, treated with proteinase-K (15  $\mu\text{g}/\text{ml}$ ) for 5 min at 37 °C and incubated with either SARS-CoV-2 (40 nM) or U6 probes (2 nM) for one hour at 54 °C in a hybridizer. After washing with SSC buffer, the presence of SARS-CoV-2 RNA was detected using an anti-DIG alkaline phosphatase (AP) antibody (1:500) (Roche Diagnostics) supplemented with sheep serum (Jackson Immunoresearch) and bovine serum albumin (BSA). Hybridization was detected by adding NBT-BCIP substrate (Roche Diagnostics). Nuclei were counterstained with nuclear fast red.

### Plasmids

The expression plasmid pEC117-Spike-V5 was generated as follows: the SARS-CoV-2 wild type protein (NCBI accession number NC\_045512.2, position 21563-25384) was codon-optimised and synthesized in two fragments of approximately 2 kb each as gBlock DNA fragments (IDT Integrated DNA Technologies) with the in-frame addition of the V5 tag at the C-terminus, and then cloned into the pZac 2.1 backbone under the control of the cytomegalovirus (CMV) IE promoter. The construct DNA sequences were verified by Sanger sequencing. The following expression vectors were used: hTMEM16A (GenScript OHu26085D), hTMEM16F (GenScript OHu26351D), hACE2 (Addgene 1786), pGCamp6s (Addgene 40753), pMERS-CoV-S and pSARS-CoV-1-S (W. Barclay laboratory), pCMV-EGFP and pmCherry-NLS (the last two obtained from L. Zentilin, ICGEB, Trieste, Italy).

### siRNA transfection

The siRNAs (Dharmacon siGENOME SMARTpools, 4 siRNAs per gene target) targeting ACE2 (M-005755-00-0005), ANO1/TMEM16A (M-027200-00-0005), TMEM16B (M-016745-01-0005), TMEM16E (M-026787-00-0005), TMEM16F/ANO6 (M-003867-01-0005) and Xkr8 (M-015745-01-0005) were dispensed onto the bottom of 96-well microplates (CellCarrierUltra 96, PerkinElmer); siRNA buffer and a non-targeting siRNA were used as controls. Briefly, the transfection reagent (Lipofectamine RNAiMAX, Life Technologies) was diluted in Opti-MEM (Life Technologies) and added to each siRNA in the microplate array. Thirty min later,  $6.5 \times 10^3$  Vero cells or  $8 \times 10^3$  HEK293T cells were seeded in each well. All siRNAs were tested at different concentrations ranging from 6 nM to 50 nM. Twenty-four hr after siRNA transfection, 100 ng of either pEC117-Spike-V5 or pCMV-EGFP expression

## Article

plasmid was transfected using a standard forward transfection protocol. Briefly, pDNA was diluted in Opti-MEM (Life Technologies), mixed with the transfection reagent (FuGENE HD, Promega) using the following ratios: 1  $\mu$ g pDNA:3  $\mu$ l FugeneHD. The mix was incubated 20 min at RT and added to the siRNA-transfected plates. After 24 hr, cells were fixed in 4% PFA and processed for immunofluorescence. For gene silencing experiments, the indicated siRNAs were transfected into Vero/HEK cells using a standard reverse transfection protocol, at a final concentration of 25 nM. Briefly, the transfection reagent (Lipofectamine RNAiMAX, Life Technologies) was diluted in Opti-MEM (Life Technologies) and added to the siRNAs arrayed in 12-well plates; 30 min later,  $-1.2 \times 10^5$  cells were seeded per well. After 48-72 hr, cells lysates were analysed by qPCR and/or western blotting, as detailed later.

### Phosphatidylserine (PS) externalisation assay

Vero cells were transfected with either pEC117-Spike-V5 and pmCherry-NLS or an empty pZac 2.1 vector, or reverse transfected with indicated siRNAs as described above. On the day of test, cells were seeded in 96-well microplates with a flat and clear bottom (CellCarrierUltra 96, Perkin Elmer) at a density of 6500 cells/well for 2 hr. Cells were then treated with different drug concentrations for 1 hr. After one wash with medium without FBS at RT, cells were incubated with 100  $\mu$ l 1:100 AnnexinXII (pSIVA Abcam #ab129817), with or without 5-10  $\mu$ M ionomycin. Cells were then immediately imaged by fluorescence microscopy using an Operetta CLS microscope mounting a 20x NA1.1 lens. Nine images/well were automatically acquired at 3 different wavelengths: 1) Ex 460-490nm, Em 500-550nm (AnnexinXII "Green"); 2) Ex 530-560, Em 570-650nm (mCherry-NLS "Red"); 3) Brightfield; 4) Digital phase contrast.

### Calcium imaging

Cells were seeded in 10-cm Petri dishes (1.2 million cells per dish) to reach 70-80% confluency on the subsequent day and reverse transfected with indicate siRNAs. Co-transfection was performed using 5  $\mu$ g pGCaMP6s and 5  $\mu$ g either indicated CoV-S plasmids or an empty pZac 2.1 vector using 30  $\mu$ l FuGENE HD Transfection Reagent (Promega #E2311) in 500  $\mu$ l of Opti-MEM medium (Life Technologies). Sixteen hr after transfection, cells were detached, washed in 1xPBS and diluted to the final concentration of  $6 \times 10^4$  cells/ml in Dulbecco's modified Eagle medium (DMEM) with 1 g/L glucose (Life Technologies) supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Life Technologies). A total of 6000 cells/well (100  $\mu$ l) were seeded in 96-well microplates with a flat and clear bottom (CellCarrierUltra 96, Perkin Elmer). For drug treatment experiments, cells were treated three hours after seeding with either 1  $\mu$ M Niclosamide (EP #N0560000), 5  $\mu$ M Clofazimine (EP #Y0000313), 5  $\mu$ M Salinomycin (SIGMA #S4526-5) or 1% DMSO. For calcium-depletion assays, cells were kept in calcium-free medium or treated with either 10  $\mu$ M Cyclopiazonic acid, CPA (Tocris #1235), 500 nM Thapsigargin, TG (Tocris #1138) or 0.1% DMSO.

Image acquisition was performed using the Operetta CLS high content screening microscope (Perkin Elmer) with a Zeiss 20x (NA=0.80) objective at 37 °C and 5% CO<sub>2</sub>. A total of 3 fields per well were imaged every 2 minutes at Ex 460-490 nm, Em 500-550 nm (GCaMP6S sensor "Green"). Images were subsequently analysed with the ImageJ software. For each frame, fluorescence intensity (F) was subtracted from the same frame in the preceding acquisition to remove the background signal and to calculate  $\Delta F/F_0$  index, where  $F_0$  is the median baseline fluorescence and  $\Delta F = F - F_0$ . For intensity analysis, more than twelve 180- $\mu$ m<sup>2</sup> Regions Of Interest (ROI) per condition were considered, compiling a total of at least 50 GCaMP6s-positive cells per condition. For each ROI, positive  $\Delta F$  values (i.e., increase) were taken into account with the BAR script "Find peaks". Among these, values outside 1.5 times the interquartile range above the upper quartile were considered as "spikes". Single cell spike frequency was then counted for the whole observation period.

### RNA extraction and real-time PCR

Total mRNA was isolated from HEK293T or Vero cells 48-72 hrs after siRNA transfection using a standard Trizol RNA extraction protocol. The RNA obtained (0.5-1  $\mu$ g) was reverse-transcribed using MLV-RT (Invitrogen) with random hexameric primers (10  $\mu$ M) in a 20- $\mu$ l reaction following the manufacturer's instructions. Quantification of TMEM16A (Hs00216121\_m1), TMEM16B (Hs00220570\_m1), TMEM16E (Hs01381106\_m1) and TMEM16F (Hs03805835\_m1) gene expressions was performed by quantitative Real-Time PCR using Taqman probes and primers for SYBR Green analysis (primers in Supplementary Information Table 3). Expression of the housekeeping gene GAPDH (Hs02786624\_g1) was used for normalization.

Amplifications were performed using a QuantStudio3 machine using TaqMan™ Gene Expression Master Mix (Applied Biosystems 4369016). The Real-Time qPCR profile was programmed with a standard protocol, according to the manufacturer's instructions. Supplementary Information Table 3 lists the primer sequences used in the real-time PCR assays.

### Western blotting

After 48-72 hr siRNAs transfection, HEK293 cells were harvested and homogenized in RIPA lysis buffer (20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate supplemented with protease inhibitors (Roche)) for 10 min at 4 °C and sonicated by using Bioruptor (Diagenode) for 30 min. Equal amounts of total cellular proteins (15-20  $\mu$ g), as measured with the Bradford reagent (Biorad), were resolved by electrophoresis in 4-20% gradient polyacrylamide gels (Mini-PROTEAN, Biorad) and transferred to nitrocellulose/PVDF membranes (GE Healthcare). Membranes were blocked at RT for 60 min with PBST (PBS + 0.1% Tween-20) with 5% skim milk powder (Cell signalling, 9999). Blots were then incubated (4 °C, overnight) with primary antibodies against ACE2 (diluted 1:1000), TMEM16F (1:1000),  $\beta$ -actin (diluted 1:5000), V5 (diluted 1:5000) or TMEM16F (diluted 1:500), TMEM16A (diluted 1:500) and TMEM16B (diluted 1:1000). Blots were washed three times (5 min each) with PBST. For standard Western blotting detection, blots were incubated with either anti-rabbit HRP-conjugated antibody (1:5000) or anti-mouse HRP-conjugated antibody (1:10,000) for 1 hr at RT. After washing three times at RT with PBST (10 min each), blots were developed with ECL (Amersham).

### Electrophysiology

Whole cell patch clamp recordings were carried out on HEK293 cells grown on glass cover slips coated with poly-L lysine. Following plating, cells were transfected the following day with either EGFP or a combination of EGFP, Spike and ACE2. Recordings were typically carried out 12-36 hr after transfection. TMEM16F knockdown experiments were carried out as above by transfecting HEK293 cells with either a control siRNA (NT1) or a TMEM16F/ANO6-targeting siRNA. Delivery of siRNA was done by plating  $500 \times 10^3$  HEK293 cells together with 12.5 nM siRNA per well of a 12-well plate. Twenty-four hr after siRNA transfections, cells were transfected with a pCMV-EGFP expression plasmid as described. Six hr after transfection, cells were plated onto 18 mm diameter glass cover slips coated with poly-L-lysine seeded at  $10 \times 10^3$  cells per well, and recorded 12 to 36 hr after plating.

Whole-cell recordings were performed in an HBS extracellular solution (pH 7.3, 315 mOsm) that contained (in mM): 139 NaCl, 2.5 KCl, 10 HEPES, 10 Glucose, 1.3 MgCl<sub>2</sub> and 2 CaCl<sub>2</sub>. Patching electrodes were made from thick-walled borosilicate glass (O.D: 1.5mm, I.D: 0.86  $\mu$ m, Sutter Instruments) obtaining a resistance between 3-4 M $\Omega$  and filled with an intracellular solution containing (in mM): 130 CsCl, 10 HEPES, 10 EGTA, 1 MgATP, 1 MgCl<sub>2</sub> and free Calcium adjusted to 28  $\mu$ M using CaCl<sub>2</sub> according to calculations using MAXchelator Ca-Mg-ATP-EGTA Calculator v1.0 software. Solution was adjusted to a pH of 7.4 using CsOH and osmolarity to 290 mOsm. Recordings were obtained with

a Multiclamp 700B amplifier (Molecular Devices) and digitised with the Digidata 1440A digitizer (Molecular Devices). Data was acquired with the software Clampex v10.3.1.5 (Molecular Devices) and Axon Multiclamp 700B Commander Software (Molecular Devices). Signals were sampled at 5 kHz and filtered at 2.5 kHz. Pipette offsets were nulled before seal formation and pipette capacitance was compensated in the cell-attached configuration once a giga-seal was obtained. We used responses to hyperpolarising and depolarising steps to estimate the series resistance ( $R_s$ ) of the recording, the membrane resistance ( $R_m$ ; from the steady holding current at the new voltage) and membrane capacitance ( $C_m$ ; from the area under the exponentially decaying current from peak to holding). Recordings were excluded if access resistance exceeded 15 M $\Omega$  and if input resistance was lower than 150 M $\Omega$ . All recordings were carried out at room temperature.

Our strategy was to target cells that were mononuclear (cells that had not fused yet), as we found that we were unable to obtain stable recordings from large syncytia. Although it is possible that some of the recordings of the Spike-expressing cells include early stage syncytia, they are unlikely to contain more than 2 nuclei. In fact, the mean membrane capacitance, an indirect measure of cell size, was not significantly different between the different experimental groups. Nevertheless, to avoid any issues with cell size, all currents were expressed as current density. Cells were held at 0 mV and ramps consisted of either a short 20 ms step to -80 mV followed by 500 ms ramp from -80 to +80 mV or a longer 300 ms step to -80 mV followed by 500 ms ramp from -80 to +80 mV. Data was pooled from both as there was no significant difference in the current responses. To remove the leak current from the ramp protocols, a line was fit to the current measured from -80 to -20 mV and subtracted from the entire curve. The resulting ramps showed clearly identifiable outwardly rectifying currents that reversed at 0 mV. Analysis was carried out using custom written routines in Matlab v. R2019a and on Prism v. 9.0.1 (GraphPad).

### SARS-CoV-2 infection

SARS-CoV-2/England/IC19/2020 (IC19), isolated on Caco2 cells from a clinical sample collected from a patient admitted to St. Mary's Hospital in London, United Kingdom, was used for the cell protection assays. Cell survival upon viral infection was measured by fixing the cells in 4% PFA, followed by quantification, using HC microscopy, of the total cell area/well using DPC (Digital Phase Contrast) imaging.

SARS-CoV-2 strain England 02/2020/407073 to study drug antiviral effect was provided by Public Health England (courtesy of Maria Zambon and Hannah McGregor<sup>48,49</sup>). For the drug inhibition assays, drugs were diluted in DMSO and added to 96-well plates of Vero E6 cells for 2 hr. Virus was added at an MOI 0.05 for 1 hr, the cells washed with PBS and then cultured in fresh drug-containing medium for a further 48 hr. Virus production in the culture supernatants was quantified by plaque assay using Vero E6 cells. The IC50 value was defined as the drug concentration at which there was a 50% decrease in the titer of supernatant virus. Data were analysed using Prism 8.0 (GraphPad), and

IC50 values were calculated by non-linear regression analysis using the dose-response (variable slope) equation.

### Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

### Data availability

There are no restrictions on data availability. CAS numbers for the investigated drugs are reported in the manuscript. All data are reported in the manuscript main text or supplementary material.

47. Gabisonia, K. *et al.* MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. *Nature* **569**, 418–422, <https://doi.org/10.1038/s41586-019-1191-6> (2019).
48. Seow, J. *et al.* Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* **5**, 1598–1607, <https://doi.org/10.1038/s41564-020-00813-8> (2020).
49. Carter, M. J. *et al.* Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nat Med* **26**, 1701–1707, <https://doi.org/10.1038/s41591-020-1054-6> (2020).

**Acknowledgements** The authors are grateful to Stuart Neil, Alison Cave, Giovanna Giacca, Alexandar Ivetic and all the other members of the Giacca lab who contributed from home during the lockdown period for helpful comments. The authors wish to acknowledge the generosity of Norman Leblanc, Kazi Mirajul Hoque, Mikio Hayashi and Iain Greenwood for their gift of reagents and thank Marcio Guiomar Oliveira for assisting in preparing the cell cultures for electrophysiology. This work was supported by grants from the King's College London King's Together programme (to MG and MHM); British Heart Foundation (BHF) Programme Grant RG/19/11/34633 (MG); King's College London BHF Centre of Research Excellence grant RE/18/2/34213 (AMS, MG); European Research Council (ERC) Advanced Grant 787971 "CuRE" (MG); Wellcome Trust Investigator Awards (215508/Z/19/Z to JB and 106223/Z/14/Z to MHM), BBSRC project grant BB/S000526/1 (JB), Huo Family Foundation (MHM), National Institute of Allergy and Infectious Diseases (U54AI150472 and R01AI076119, MHM) and National Institute for Health Research Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust and King's College London (IS-BRC-1215-20006, AMS, MHM, MG).

**Author contributions** LB performed the HTS screenings; HA, IS and LB performed most cellular biology studies (PS externalization, effect of plasmid overexpression, RNAi studies). HA performed the immunoblottings. IS performed the time-lapse imaging studies. EC performed expression vector cloning and analysis of Spike intracellular trafficking. GN and JB performed the electrophysiology study. DG, RP and WB performed studies on the effect of drugs on Vero and Calu-3 cell protection from SARS-CoV-2; JM-J-G, AMO-P and MM performed antiviral activity experiments against SARS-CoV-2 and RNAi studies on Vero and Calu-3 cells; RB performed autopsies and histology on patients' samples; AC provided consultancy on clinical drug mechanism of action; GR performed investigations on the effect of Spike on cellular pathways; CC performed immunohistochemistry on patients' samples; ES performed in situ RNA hybridisation on patients' samples; DA provided consultancy and reagents for chloride channel studies; AMS provided advice on the design and the clinical aspects of the study. MG conceived and coordinated the study. IS, EC, GN, DG contributed equally.

**Competing interests** King's College London has filed a patent application on the methods used to detect SARS-CoV-2 Spike protein-induced syncytia as described in this manuscript.


### Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41586-021-03491-6>.

**Correspondence and requests for materials** should be addressed to M.G.

**Peer review information** *Nature* thanks Lily Jan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at <http://www.nature.com/reprints>.



Extended Data Fig. 1 | See next page for caption.


**Extended Data Fig. 1 | Syncytia induced by coronavirus Spike proteins.**

**a**, Syncytial pneumocytes in the lungs of COVID-19 patients.

Immunohistochemistry using the indicated antibodies, x40. Further information on the patients' cohort and is in ref. <sup>15</sup>. **b**, In situ hybridization using two LNA-modified RNA probes for the SARS-CoV-2 genome (upper four panels) and immunohistochemistry with an anti-Spike antibody. Lung samples from individuals who died in 2018 for other causes served as negative controls for this analysis, while a positive control was hybridization with a probe for the ubiquitous U6 RNA, as per our previous experience<sup>47</sup>, which showed nuclear localization in all cells. Scale bar: 50  $\mu$ m. Further information on the in situ hybridization technique is in ref. <sup>15</sup>. **c**, Cytological alterations induced by Spike

protein. Vero cells were transfected with a Spike-expressing plasmid and cultured for 12 hr; Spike protein was then visualised by IF and cell body stained using HCS CellMask DeepRed. Spike-positive cells show marked morphological alterations, including presence of numerous filopodia (inset in the leftmost panel) and membrane protrusions contacting the plasma membrane of neighbouring cells. Scale bar: 50  $\mu$ m. **d** and **e**, Syncytia induced by other coronavirus Spike proteins. Vero cells were transfected to express the Spike protein of MERS-CoV, SARS-CoV or SARS-CoV-2. After 24 hr, cells were immuno-stained for nuclei (white). Representative images are in **d**, and quantifications in **e**. Data are mean $\pm$ SEM; n=4). \*\* $P$ <0.01, one-way ANOVA with Bonferroni correction.


ACCELERATED ARTICLE PREVIEW



Extended Data Fig. 2 | See next page for caption.

**Extended Data Fig. 2 | Cell Fusion Inhibition Assay (CFIA).** **a.** Scheme of Cell Fusion Inhibition Assay (CFIA). The assay is based on the co-culture, for 12 hr, of Vero cells with U2OS cells transiently transfected to express Spike. To permit quantitative assessment of cell fusion by HC microscopy, the Spike “donor” U2OS cells are loaded with quantum dots (Q-dots) emitting at 525 nm (green) while the “acceptor” Vero cells with Q-dots emitting at 800 nm (red). Screenings were performed in 384-well plates by co-plating Q-dot loaded “donor” and “acceptor” cells, followed by drug treatment at 10  $\mu$ M standard concentration. After 24 hr, cells were fixed and processed by HC microscopy. Multiple control wells with 1% DMSO and no drugs were included in each plate. **b.** Fluorescent images of co-cultured U2OS (Green Q-dots) and Vero (Red Q-dots) cells. Cells are stained with HCS CellMask Blue; fused cells (heterokaryons) are identified as cells having more than two nuclei and containing both green and red Q-dots in their cytoplasm. Thus, the CFIA assay scores for the effect of drugs on the fusion of heterologous cells and detects inhibitors that block fusion of as few as two cells. The assay has >5-fold dynamic range. Scale bar: 100  $\mu$ m **c.** CFIA image high content analysis pipeline. Images were analysed using the Harmony software (PerkinElmer). The cytoplasmic area, stained by the HCS Cell Mask Blue, was defined using the “Find Cytoplasm” analysis module (Harmony) and the number of either green or red spots was counted using the “Find Spots” analysis module (Harmony). All the cells that scored a nuclear area greater than 5 times the average area of a single nucleus and were simultaneously positive for at least two red and two green dots were considered as fused (highlighted in green). Data were expressed as a

percentage of fused cells. **d.** Cumulative results of CFIA screening of FDA/EMA approved drug libraries. We screened two FDA/EMA-approved drug libraries, The Spectrum Collection, MS Discovery System, Inc. and the Prestwick Chemical Library, Prestwick Chemical; 2545 and 1280 individual small molecules respectively. The graph shows the cumulative results of the two screenings. The percentage of syncytia normalized on total cells is plotted as z score. Compounds with a z-score  $\leq$  -2.58 (red dotted line, 0.005% tail of the distribution) are shown in red, those between  $\leq$  -1.96 (0.025% tail, blue dotted line) and -2.58 are in blue. In the Prestwick collection, 34 drugs inhibited S-mediated fusion with a z score < -1.96, of which 8 with a z score of < -2.58. In the MS Discovery Spectrum collection, 54 drugs performed at a z score < -1.96 of which 14 with a z score of < -2.58. All untreated controls for both libraries had a z score in the  $\pm$  0.40 range. **e.** Analytic evaluation of CFIA results. A correlation chart between the percentage of syncytia/well and the total number of cells/well is shown for the two screened drug libraries. Drugs showing a total number of cells at  $\geq$  2 standard deviations lower than the average of all drugs (red dotted line) considered toxic and not included in the subsequent analysis. Distribution of control wells (1% DMSO) is shown by a green box. **f.** Distribution frequency of the % of syncytia plotted as the number of drugs vs. the z score of the % of syncytia/well; toxic cells were excluded as in panel e. Blue dotted lines are at z scores  $\pm$  1.96 and red dotted lines at z scores  $\pm$  2.56. The numbers of drugs are shown. **g.** Correlation chart for the common drugs between the two libraries. Data are plotted as the z score of the % of syncytia/well. Blue and red lines are as above.




Extended Data Fig. 3 | See next page for caption.

**Extended Data Fig. 3 | Results of SIA.** **a**, Analysis of CFIA results. Correlation chart between the percentage of syncytia/well and the total number of cells/well. Data are presented as in Extended Data Fig. 2e. **b**, Distribution frequency of the screening results. Data are shown as in Extended Data Fig. 2f. **c**, Correlation chart for the common drugs between the two libraries. Data are shown as in Extended Data Fig. 2g. **d**, Representative immunofluorescence images for Spike protein (green), cell body (red, using HCS CellMask DeepRed) and nuclei (blue, Hoechst) of cells treated with the indicated drugs increasing syncytia formation compared to control, DMSO-treated cells. The number of syncytia is shown at the bottom of each image pair as percentages of total

nuclei. Scale bar: 500  $\mu$ m. Representative images in one of six wells. **e**, Dose-response effect on syncytia formation of Niclosamide, Clofazimine and Salinomycin. The graphs show the effect of different doses of the three drugs on syncytia formed by Vero and HEK/ACE2 cells in response to Spike expression. Cells were transfected with pEC117-Spike-V5 and, 12 hr later, treated with the indicated drug concentrations for additional 24 hr. Syncytia were quantified by HC microscopy and are expressed as percentage of cell nuclei (n=6 wells/dose; data are mean $\pm$ SD). Cell viability was assessed by HC counts of the number of nuclei in each well.

ACCELERATED ARTICLE PREVIEW





Extended Data Fig. 5 | See next page for caption.


## Article

### Extended Data Fig. 5 | Cell protective ability of drugs against SARS-CoV-2.

**a**, List of drugs (CAS # and chemical name) shortlisted from the syncytia assays and tested with infectious SARS-CoV-2. **b**, Effect of drugs on cell viability. Vero E6 cells were preincubated with a selection of drugs at 10  $\mu$ M for 2 hr before 100 TCID<sub>50</sub> of IC19 was added. After 5 days, cells were fixed in 4% PFA. Cells survival was quantified by densitometry as the total cell area/well (average of 2 replicates). Drugs labelled with Tox showed a cytotoxic effect at the used concentration independent of viral infection. Drugs in green were further tested for dose-dependent response. **c**, Dose-dependent cell protection of selected drugs against SARS-CoV-2 infection. Cells were preincubated with drugs or a negative DMSO control at different concentrations for 2 hr before 100 TCID<sub>50</sub> of IC19 was added. After 3 days, cells were fixed in 4% PFA and cell survival was quantified by HC microscopy as the total cell area/well using DPC (Digital Phase Contrast) imaging (n=3). The image shows one of the replicates. Niclosamide and Salinomycin protected against virus-induced cell lysis across a wide range of concentrations from 5  $\mu$ M down to 39 nM for Niclosamide and Salinomycin, while Clofazimine showed a dose dependent cytoprotective effect above 1  $\mu$ M. For Sertraline and Deptropine, the cytoprotective effect was

only above 2.5  $\mu$ M and close to the drug-alone cytotoxic effects (which were assessed separately; not shown). **d**, Inhibition of SARS-CoV-2 viral replication by selected drugs in Calu-3 respiratory cells. Cells were preincubated with drugs (Niclosamide 2.5  $\mu$ M, Clofazimine 5  $\mu$ M and Salinomycin 2.5  $\mu$ M) for 2 hr and then infected with SARS-CoV-2. After 1 hr, cells were washed with PBS and then cultured in fresh drug-containing medium for a further 48 hr. Virus production in the culture supernatants was quantified by plaque assay using Vero E6 cells. The graphs show virus production in the culture supernatants quantified by plaque assay using Vero E6 cells (mean $\pm$ SEM; n=7). \*\* $P$ <0.01, one-way ANOVA with Bonferroni post-hoc correction. **e**, Representative images of syncytial Calu-3 cells positive for SARS-CoV-2 infection. Cells were immunostained for S-protein (green), and nuclei (blue). **f**, Inhibition of syncytia by Niclosamide after SARS-CoV-2 infection. Calu-3 cells were preincubated with Niclosamide 2.5  $\mu$ M and then infected with SARS-CoV-2 in the presence of the drug. After 1 hr, cells were washed with PBS and then cultured in fresh drug-containing medium. After 48 hr, cells were immunostained for Spike (green), Nucleocapsid (red) and nuclei (blue). Scale bar: 200  $\mu$ m.

ACCELERATED ARTICLE PREVIEW




Extended Data Fig. 6 | See next page for caption.

## Article

**Extended Data Fig. 6 | Effect of drugs on Ca<sup>2+</sup> oscillations.** **a**, Amplitude of calcium transient peaks per group of 4 GCaMP-positive cells in average in at least twelve 180  $\mu\text{m}^2$  ROI per condition. Vero cells co-transfected with GCaMP6s and either an empty vector (grey bars) or with Spike (green bars) and treated with the specified drugs. Data are expressed as  $\Delta F/F$ ; box: 25th-75th percentiles and median, whiskers: min-max values; \*\* $P < 0.01$ , Kruskal-Wallis, two-sided, with Dunn's correction for multiple comparisons. **b**, Distribution of transient frequencies of single cells in 400 min analysis. Data are expressed as percentage of cells. Results from at least 50 cells per condition are shown. \* $P < 0.05$ , \*\* $P < 0.01$ , Kruskal-Wallis, two-sided, with Dunn's correction for multiple comparisons. **c**, Calcium transients over time in Vero cells co-


transfected with GCaMP6s and either an empty vector (left panels) or with Spike (right panels) and the indicated treatment. Data are expressed as  $\Delta F/F$  over time (min); every line is one of at least twelve 180  $\mu\text{m}^2$  ROI per condition, representing a group of 4 GCaMP positive cells on average. **d**, Amplitude of calcium transient peaks per group of 4 GCaMP-positive cells on average in at least twelve 180  $\mu\text{m}^2$  ROI per condition. Vero cells co-transfected with GCaMP6s and either an empty vector (grey bars) or with Spike (green bars) and treated as indicated. Data are expressed as  $\Delta F/F$ ; box: 25th-75th percentiles and median, whiskers: min-max values; \*\* $P < 0.01$ , Kruskal-Wallis, two-sided, with Dunn's correction for multiple comparisons.

ACCELERATED ARTICLE PREVIEW



**Extended Data Fig. 7 | Induction of Ca<sup>2+</sup> oscillations by coronavirus Spike proteins and upon ACE2 and TMEM16F knockdown. a and c,** Calcium transients over time in Vero cells co-transfected with GCaMP6s and the indicated plasmids and siRNAs. Data are expressed as  $\Delta F/F$  over time (min); every line is one of at least twelve 180  $\mu\text{m}^2$  ROI per condition, representing a


group of 4 GCaMP positive cells on average. **b and d,** Amplitude of calcium transient peaks per group of 4 GCaMP-positive cells in average in at least 12 180  $\mu\text{m}^2$  ROI per condition. Data are expressed as  $\Delta F/F$ ; box: 25th-75th percentiles and median, whiskers: min-max values; \* $P < 0.05$ , \*\* $P < 0.01$ , Kruskal-Wallis, two-sided, with Dunn's correction for multiple comparisons.



**Extended Data Fig. 8 | Levels of expression of TMEM16 family members.**

**a**, Expression profiles of the 10 known TMEM16 proteins in different cell types and primary human respiratory cells. RNA was prepared from the indicated cell lines and from primary bronchial human airway epithelial cells. Levels of mRNA quantified by real-time PCR are expressed relative to GAPDH mRNA. Data are mean  $\pm$  SEM of 3 independent experiments. **b**, Western blot showing the levels of TMEM16F and TMEM16A in basal conditions and upon overexpression, and after transfection of V5-tagged SARS-CoV-2 Spike. Beta-actin was used as a

loading control. Representative blot of three independent repetitions. **c**, Expression of TMEM16A (upper panel) and TMEM16F (lower panel) in the presence of the top 5 selected drugs. RNA was prepared from the HEK293/ACE2 cells transfected either with Spike or control plasmids in the presence of the indicated drugs for 24 hr. The mRNA levels of TMEM16A and TMEM16F were quantified by real-time PCR and are expressed as fold over control condition (DMSO), after normalisation over the GAPDH housekeeping mRNA. Data are mean  $\pm$  SEM of 3 independent experiments.




Extended Data Fig. 9 | See next page for caption.

## Article

**Extended Data Fig. 9 | Expression of TMEM16A, TMEM16F and ACE2 in different experimental conditions. a,** Levels of expression of the genes investigated in this study upon their individual knockdown in Vero, HEK293/ACE2 and Calu-3 cells. RNA was prepared from the different cell lines after transfection with the indicated siRNAs (siNT1-control non-targeting siRNA1) and mRNA levels were quantified by real-time PCR. Data are expressed as fold over mock-treated cells after normalized over the GAPDH housekeeping mRNA. Data are mean  $\pm$  SEM of 3 independent experiments. **b,** Western blotting analysis showing the levels of ACE2 and TMEM16F in the presence of Spike after

silencing selected genes (ACE2, TMRSS2, TMEM16A, TMEM16B, TMEM16E, TMEM16F and Xkr8). The amount of Spike, ACE2 and TMEM16F measured by immunoblotting is shown after cell treatment with the respective siRNAs. The levels of Spike, ACE2 and TMEM16F proteins were assessed by immunoblotting with anti-V5, anti-ACE2 and anti-TMEM16F antibodies respectively. Beta-actin was used as a loading control protein. Representative blot of three independent repetitions. **c,** Same as in panel b in HEK293/ACE2 cells. The blot with the anti-TMEM16A antibody did not detect any band of the expected mass (cf. also Extended Data Fig. 7b).

ACCELERATED ARTICLE PREVIEW




Extended Data Fig. 10 | See next page for caption.

## Article

**Extended Data Fig. 10 | Current density and phosphatidylserine (PS) externalisation. a.** Results of whole-cell voltage-clamp recordings of HEK293 cells measuring current density in response to a voltage ramp. Currents were measured using a 500 ms voltage ramp from -80 to +80 mV in Control cells (Cont; black trace,  $n = 34$ ; same as controls for **Fig. 4c-e**; recorded with 28 mM intracellular calcium), in cells treated with the benchmark TMEM16 channel antagonist benzbramarone (Bbz, 10 mM; brown trace,  $n=3$ ) or recorded with a low intracellular calcium concentration (Low [Ca], 0.5 mM; blue trace,  $n = 21$ ) ( $n=4$ ). The inset shows the current density measured at +75 mV (\*\* $P < 0.01$ , Kruskal-Wallis, two-sided, with Dunn's post hoc multiple comparisons). All values are displayed as mean  $\pm$  SEM. **b and c.** Inhibition of PS exposure after treatment TMEM16F siRNA and indicated drugs. Representative image of Vero cells reverse-transfected with the indicated siRNAs and stained for Annexin XII

without (upper panels) or with (lower panel) ionomycin induction (10  $\mu$ M). Annexin in green, phase contrast in grey, scale bar: 500  $\mu$ m. Enlargement in c. Selected images and quantification in **Figs. 4f and 4g. d.** Representative image of Vero cells treated with 100 nM Niclosamide, 500 nM Clofazimine or 500 nM Salinomycin and stained for Annexin XII without (upper panels) or with (lower panel) ionomycin induction (5  $\mu$ M). Annexin in green, phase contrast in grey, scale bar: 500  $\mu$ m. Enlargement in b. Selected images and quantification in **Figs. 5h and 5i. e.** Annexin XII reactivity (PS externalisation) of syncytia expressing the Spike protein. Cells were transfected with the S-expressing plasmid and a plasmid expressing mCherry carrying a nuclear localisation signal (orange nuclei). Scale bar: 500  $\mu$ m. Representative image of over 10 syncytia in at least 3 independent experiments.

ACCELERATED ARTICLE PREVIEW



Extended Data Fig. 11 | See next page for caption.

## Article

**Extended Data Fig. 11 | TMEM16F is involved in SARS-CoV-2 Spike-induced syncytia formation.** **a** and **b**, Inhibition of syncytia formation in Calu-3 cells by the downregulation of TMEM16F. Calu-3 cells were first silenced for each of the indicated genes or treated with siNT1 (non-targeting siRNA1 as negative control) and then, after 24 hr, transfected to express the S-protein. After additional 24 hr, cells were immunostained for Spike (green) and nuclei (blue). Representative images are in **a** (scale bar: 500  $\mu\text{m}$ ), quantification in **b**. Data (mean $\pm$ SD; n=3) are plotted as percentage of syncytia (cell area  $\geq$  20000  $\mu\text{m}^2$ ) normalized on the total number of cells and expressed as fold over mock (lipid-only)-treated cells. \* $P$ <0.05, \*\* $P$ <0.01, one-way ANOVA with Dunnett post-hoc correction. **c** and **d**. Effect of individual siRNAs forming the Dharmacon siRNA Pool against TMEM16F (ANO6). The picture shows the efficiency of syncytia formation after transfection of Spike cDNA in Vero cells in which TMEM16F was downregulated using the 4-siRNA Pool (which was used in all the other experiments in this study) or the individual siRNAs forming this Pool (siDH\_1-4). We found that the commercial siDH\_2 siRNA does not match with the TMEM16F sequence. Data in panel **d** are mean $\pm$ SD, plotted as percentage of syncytia

(cell area  $\geq$  20000  $\mu\text{m}^2$ ) normalized on the total number of cells and expressed as fold over mock (lipid-only)-treated cells. \*\* $P$ <0.01, one-way ANOVA with Dunnett post-hoc correction. **e** and **f**, Effect of selected siRNAs on MERS-CoV and SARS-CoV-2-induced syncytia formation. Vero cells were first silenced for each of the indicated genes (ACE2 and TMEM16F) or treated with siNT1 (non-targeting siRNA1 as negative control) and then, after 24 hr, transfected to express the either MERS or SARS-CoV Spike protein. After additional 24 hr, cells were immunostained for nuclei (white). Representative images are in the panels on the left side, quantification in the bar chart on the right side. Data (mean $\pm$ SEM; n=3) are plotted as percentage of syncytia normalized on the total number of cells and expressed as fold over mock (lipid-only)-treated cells. \* $P$ <0.05, \*\* $P$ <0.01, one-way ANOVA with Bonferroni post-hoc correction. **g**, TMEM16F overexpression induces S-mediated syncytia formation. HEK293/ACE2 cells were co-transfected with human TMEM16A or TMEM16F together with a Spike-expressing plasmid. After additional 24 hr, cells were immunostained for Spike (green), TMEM16F (red) and nuclei (blue). Selected images and quantification in **Figs. 5l** and **5m**. Scale bar: 200  $\mu\text{m}$ .

ACCELERATED ARTICLE PREVIEW

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection Image analysis for high content microscopy analysis was performed using the Harmony v 4.9 software package (PerkinElmer)

Data analysis Statistical analysis was performed using GraphPad Prism 8.0 or 9.0. Analysis of electrophysiology results carried out using Matlab v. R2019a

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

There are no restrictions on data availability. CAS numbers for the investigated drugs are reported in the manuscript. All data are reported in the manuscript main text or supplementary material

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample-size pre-determination was performed. The HTS screenings were performed in two biological replicates with 3 wells/drug in 384-well plates. All the other experiments involving the use of drugs, siRNAs or expression plasmids were performed in 96-well plates in which each condition was tested in 3-8 independent wells. These sample sizes are in agreement with published reports on the effects of the individual treatments on the respective targets (cf. specific citations in the manuscript).
Data exclusions	Drugs showing toxicity on cell viability in the two HTS screenings were excluded from further analysis. Toxicity was defined as a reduction in the number of nuclei $\geq 2$ standard deviations less than the average of all drugs.
Replication	All attempts at replication were successful by our best efforts. All experiments were performed at least in triplicate (and often more times) independently with reproducible results
Randomization	Experiments were performed on cultured cells uniformly plated in 96-well plates or glass slides (for electrophysiology), with random allocation of treatment (virus, chemicals, siRNAs and plasmids).
Blinding	Blinding was not applicable to our investigation, given the nature of the reagents used (chemicals, siRNAs and plasmids). All the critical experiments were repeated independently by at least two of the investigators.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

Antibodies used	Antibodies against the following proteins were used: TMEM16A (Abcam, ab64085), TMEM16F (Abcam ab234422 and Sigma-Aldrich HPA038958-100UL), ACE2 (Abcam ab87436 and ab15348), V5 (Thermo Fisher Scientific R96025), V5-488 (Thermo Fisher Scientific 377500A488), mouse-HRP (Abcam ab6789), rabbit-HRP (Abcam ab205718), b-actin-HRP (Sigma-Aldrich A5316), Napsin (Roche 760-4867), Surfactant B (Thermo Fisher Scientific MS-704-P0), mouse-Biotin (Vector Laboratories BA-9200), SARS-CoV-2 Spike protein (GeneTex GTX632604), SARS-CoV-2 Nucleocapsid antibody (Sino Biological 40143-R001)
Validation	Antibodies against TMEM16A (Abcam, ab64085), TMEM16F (Abcam ab234422 and Sigma-Aldrich HPA038958-100UL), ACE2 (Abcam ab87436 and ab15348), V5 (Thermo Fisher Scientific R96025), V5-488 (Thermo Fisher Scientific 377500A488), b-actin-HRP (Sigma-Aldrich A5316), Napsin (Roche 760-4867), Surfactant B (Thermo Fisher Scientific MS-704-P0), mouse-Biotin (Vector Laboratories BA-9200), SARS-CoV-2 Spike protein (GeneTex GTX632604) and SARS-CoV-2 Nucleocapsid antibody (Sino Biological 40143-R001) were validated according to individual datasheets provided by the manufacturers.

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	Vero(WHO) Clone 118 cells (ECACC 88020401), Vero E6 (provided by Andrew Davidson and David Matthews, University of
---------------------	--

Cell line source(s)	Bristol UK), U-2 OS (U2OS) cells (ATCC HTB-96), HEK293T cells (ATCC CRL-3216), Calu-3 cells (ATCC HTB-55) and primary bronchial human airway epithelial cells (purchased from Epithelix).
Authentication	No cell line authentication was performed
Mycoplasma contamination	Cell lines were negative for mycoplasma contamination
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	None

## Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	<i>Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural &amp; social sciences study design questions and have nothing to add here, write "See above."</i>
Recruitment	<i>Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.</i>
Ethics oversight	<i>Identify the organization(s) that approved the study protocol.</i>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	The manuscript reports some data from post-mortem analysis of patients with COVID-19
Study protocol	<i>Note where the full trial protocol can be accessed OR if not available, explain why.</i>
Data collection	Patients' samples were collected and analysed at the University Hospital of Trieste. Use of these samples for investigation was approved by the competent Joint Ethical Committee of the Regione Friuli Venezia Giulia, Italy (re. 0019072/P/GEN/ARCS)
Outcomes	Observational study